Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Archana Garipalli"'
Autor:
Shahzad Raza, Rim Hasan, Belal Firwana, Ibrahim Yousef, Aref Al-Kali, Ahmad Zarzour, Mohamad Bassam Sonbol, Donald C. Doll, Maria Diab, Archana Garipalli, M. Hassan Murad
Publikováno v:
International Journal of Cancer. 138:1545-1553
Tyrosine kinase inhibitors (TKI) are the initial treatment for majority of newly diagnosed patients with chronic myelogenous leukemia (CML) in chronic phase (CP) and are associated with marked improvement in hematological, cytogenetic, molecular resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::257531ceff9e2a71b44a049074758c8e
https://doi.org/10.1002/ijc.29889
https://doi.org/10.1002/ijc.29889
Autor:
Belal, Firwana, Mohamad Bassam, Sonbol, Maria, Diab, Shahzad, Raza, Rim, Hasan, Ibrahim, Yousef, Ahmad, Zarzour, Archana, Garipalli, Donald, Doll, M Hassan, Murad, Aref, Al-Kali
Publikováno v:
International journal of cancer. 138(6)
Tyrosine kinase inhibitors (TKI) are the initial treatment for majority of newly diagnosed patients with chronic myelogenous leukemia (CML) in chronic phase (CP) and are associated with marked improvement in hematological, cytogenetic, molecular resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a48c3abfffeb96a79ea8ba7f8c7bf32b
https://pubmed.ncbi.nlm.nih.gov/26455714
https://pubmed.ncbi.nlm.nih.gov/26455714
Autor:
Rim Hasan, Shahzad Raza, Mohamad Bassam Sonbol, Ibraheem Yousef, Donald C. Doll, Aref Al-Kali, Maria Diab, Archana Garipalli, Belal Firwana
Publikováno v:
Blood. 124:3146-3146
Background: Tyrosine kinase inhibitors (TKI) are associated with marked improvements in molecular response and survival compared with previous therapies for patients with chronic myelogenous leukemia (CML) in chronic phase (CP). We previously reporte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::083bd5af9b8dcb26fa5cfac3b9ae9ed2
https://doi.org/10.1182/blood.v124.21.3146.3146
https://doi.org/10.1182/blood.v124.21.3146.3146